Related Experiment Video

Updated: Mar 23, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

72.4K

Effect of high-potency statins on HbA1c in patients with or without diabetes mellitus

Nobuhiro Ooba1, Shoutarou Tanaka1, Yu Yasukawa1

  • 1Department of Clinical Pharmacy, The Nihon University School of Pharmacy, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555 Japan.

Journal of Pharmaceutical Health Care and Sciences
|March 22, 2016
PubMed

Insights

High-potency statins may increase HbA1c levels in individuals with or without diabetes. This study found significant increases in HbA1c after high-potency statin initiation, highlighting potential glycemic impacts.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Statin use is associated with an increased risk of new-onset diabetes.
  • The specific impact of high-potency statins on glycated hemoglobin (HbA1c) levels remains unclear.
  • This study investigates the effect of high-potency statins on HbA1c in diverse patient populations.

Purpose of the Study:

  • To examine the effect of high-potency statins on HbA1c levels.
  • To compare HbA1c changes in patients with and without pre-existing diabetes.
  • To assess the risk of diabetes incidence associated with high-potency statin use.

Main Methods:

  • Retrospective cohort study utilizing electronic healthcare data from a Japanese general hospital.
  • Included new statin users prescribed lipid-lowering drugs between January 2010 and July 2014.
  • Compared HbA1c levels pre- and post-high-potency statin treatment using dependent t-tests and estimated hazard ratios for diabetes incidence.

Main Results:

  • In patients with diabetes (n=153), mean HbA1c increased by 0.4% (p=0.0002) after high-potency statin use.
  • In patients without diabetes (n=165), mean HbA1c significantly increased from 5.78% to 5.92% (p<0.0001).
  • A consistent trend of increased HbA1c was observed across all high-potency statins, regardless of diabetes history.

Conclusions:

  • High-potency statin therapy may lead to elevated HbA1c levels.
  • This effect is observed in both diabetic and non-diabetic individuals.
  • Further research may be warranted to understand the clinical implications of these glycemic changes.
Abstract

Keywords:
Hemoglobin A1cHigh-potency statinNew-user design

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.1K
Fixation and Operational Method for Abdominal Massage in T2DM Mice05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

853

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
912
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
989
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.7K
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
841